ArticleBlood cancer journal2021
Characterization of rare germline variants in familial multiple myeloma.
Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Germline variants in ATM, BRCA2, other cancer predisposition and novel candidate genes are implicated in glioma risk in adult glioma patients with a familial or personal history of tumors.Acta neuropathologica · 2026Article
- Multiple myeloma risk linked to DNA damage response genes.Journal of hematology & oncology · 2026Article
- Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.Leukemia · 2026Article
- Article
- Racial Health Disparity and Risk of Multiple Myeloma: Implications for Energy Balance Interventions.Cancer prevention research (Philadelphia, Pa.) · 2025Review
- FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk.Seminars in hematology · 2025Review
- Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma.Blood neoplasia · 2025Article
- Germline predisposition in multiple myeloma.iScience · 2025Article
- Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.The oncologist · 2024Article
- Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.Blood cancer discovery · 2024Article
- Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance.Blood cancer journal · 2024Article
- The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward.Pharmacogenomics and personalized medicine · 2024Review
- Article
- A germline exome analysis reveals harmfulEJHaem · 2022Article
- Rare germline deleterious variants increase susceptibility for lung cancer.Human molecular genetics · 2022Article
- Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis.Leukemia · 2022Article
- Epidemiology, genetics and treatment of multiple myeloma and precursor diseases.International journal of cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.